Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00228-020-03020-w http://scihub22266oqcxt.onion/10.1007/s00228-020-03020-w 33048175!7552959!33048175     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Pharmacol 2021 ; 77 (3): 389-397 Nephropedia Template TP {{tp|p=33048175|t=2021. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients |pdf=|usr=}}{{33048175}} gab.com Text Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients JO: Eur J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33048175 #FOAvip OBJECTIVE: To develop a population pharmacokinetic model for lopinavir boosted by ritonavir in coronavirus disease 2019 (Covid-19) patients. METHODS: Concentrations of lopinavir/ritonavir were assayed by an accredited LC-MS/MS method. The population pharmacokinetics of lopinavir was described using non-linear mixed-effects modeling (NONMEM version 7.4). After determination of the base model that better described the data set, the influence of covariates (age, body weight, height, body mass index (BMI), gender, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C reactive protein (CRP), and trough ritonavir concentrations) was tested on the model. RESULTS: From 13 hospitalized patients (4 females, 9 males, age = 64 +/- 16 years), 70 lopinavir/ritonavir plasma concentrations were available for analysis. The data were best described by a one-compartment model with a first-order input (KA). Among the covariates tested on the PK parameters, only the ritonavir trough concentrations had a significant effect on CL/F and improved the fit. Model-based simulations with the final parameter estimates under a regimen lopinavir/ritonavir 400/100 mg b.i.d. showed a high variability with median concentration between 20 and 30 mg/L (C(min)/C(max)) and the 90% prediction intervals within the range 1-100 mg/L. CONCLUSION: According to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%. Twit Text FOAVip Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients ????Eur J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33048175 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33048175 #FOAvip English Wikipedia <ref>{{Cite pmid|33048175}}</ref> Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients #MMPMID33048175 Alvarez JC; Moine P; Davido B; Etting I; Annane D; Larabi IA; Simon N Eur J Clin Pharmacol 2021[Mar]; 77 (3): 389-397 PMID33048175show ga OBJECTIVE: To develop a population pharmacokinetic model for lopinavir boosted by ritonavir in coronavirus disease 2019 (Covid-19) patients. METHODS: Concentrations of lopinavir/ritonavir were assayed by an accredited LC-MS/MS method. The population pharmacokinetics of lopinavir was described using non-linear mixed-effects modeling (NONMEM version 7.4). After determination of the base model that better described the data set, the influence of covariates (age, body weight, height, body mass index (BMI), gender, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C reactive protein (CRP), and trough ritonavir concentrations) was tested on the model. RESULTS: From 13 hospitalized patients (4 females, 9 males, age = 64 +/- 16 years), 70 lopinavir/ritonavir plasma concentrations were available for analysis. The data were best described by a one-compartment model with a first-order input (KA). Among the covariates tested on the PK parameters, only the ritonavir trough concentrations had a significant effect on CL/F and improved the fit. Model-based simulations with the final parameter estimates under a regimen lopinavir/ritonavir 400/100 mg b.i.d. showed a high variability with median concentration between 20 and 30 mg/L (C(min)/C(max)) and the 90% prediction intervals within the range 1-100 mg/L. CONCLUSION: According to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%. |Aged[MESH] |Aged, 80 and over[MESH] |Animals[MESH] |Antiviral Agents/*pharmacokinetics/therapeutic use[MESH] |Body Mass Index[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*metabolism[MESH] |Chlorocebus aethiops[MESH] |Computer Simulation[MESH] |Drug Combinations[MESH] |Female[MESH] |Humans[MESH] |Lopinavir/*pharmacokinetics/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Models, Biological[MESH] |Population[MESH] |Ritonavir/*pharmacokinetics/therapeutic use[MESH] |Survival Analysis[MESH] |Tissue Distribution[MESH]Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patient(epmc).pdf DeepDyve Pubget Overpricing